GlassScriptPhysician profile
Laura T Polliard
NPI 1356711501
$2,060.46
in general payments reported to CMS, 2019-2025
23 companies · $190 in 2025
The $190 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $341 · 2022: $724 · 2023: $114 · 2024: $692 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $973 · Education: $23.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $972.54 |
| Education | $23.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $497.26 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $336.69 | 2021-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $180.48 | 2023-2024 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $113.07 | 2021-2024 | |
| Vifor Pharma, INC. | $91.56 | 2022-2024 | Veltassa |
| Amgen INC. | $74.43 | 2024 | Tavneos |
| Travere Therapeutics, INC. | $72.86 | 2022-2024 | |
| Fresenius USA Marketing, INC. | $67.24 | 2024-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $63.70 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $62.40 | 2021-2022 | |
| Kestra Medical Technology Services, INC. | $58.46 | 2025 | Assure Wcd |
| Scpharmaceuticals INC. | $51.77 | 2024 | |
| Akebia Therapeutics INC | $47.62 | 2024 | Auryxia, Vafseo |
| Calliditas Therapeutics US INC. | $46.66 | 2022 | |
| Kyowa Kirin, INC. | $45.50 | 2023-2024 | Crysvita |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $42.17 | 2024 | Ibsrela |
| Aurinia Pharma U.S., INC. | $41.14 | 2023-2024 | Lupkynis |
| Alnylam Pharmaceuticals INC. | $38.44 | 2021-2025 | Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.05 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $28.90 | 2024 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $28.77 | 2024 | Jynarque |
| Lilly USA, LLC | $21.27 | 2024 | Jardiance |
| Abiomed | $14.02 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Polliard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.